Moreover, transfer of CD4+ T cells inhibited tumor progression in BR5-FOXL2, but not in 4T1-FOXL2, compared with control CD3+ T cells (4T1, nonsignificant; BR5 CD4+, P < 0.03) (Supplemental Figure 10, A and B). The gene discussed is CD4; the disease is neoplasm.